Covid-19 Updates and Statements

09.19.2025

ACIP COVID-19 Public Statement

09.19.2025

Pfizer-BioNTech Statement to ACIP Meeting 19th September 2025

09.16.2025

Pfizer Reaffirms Safety and Efficacy of COVID-19 Vaccines

09.15.2025

Pfizer Shares Available Analyses of Myocarditis and COVID-19 Vaccines

09.09.2025

Pfizer Upholds Commitment to Transparency and Shares Analysis of COVID-19 Vaccination in Pregnant Women

09.03.2025

Pfizer Responds to Success of Operation Warp Speed and Reaffirms Transparency of COVID Vaccine Data

05.11.2023

Global and U.S. Agencies Declare End of COVID-19 Emergency

01.27.2023

Pfizer Receives Positive CHMP Opinion for Conversion of PAXLOVID™ Conditional Marketing Authorization to Full Marketing Authorization in the European Union

12.13.2022

Pfizer to Provide U.S. Government with an Additional 3.7 Million Treatment Courses of PAXLOVID™ to Help Combat COVID-19

11.23.2022

Pfizer Signs Agreement to Provide the European Union with PAXLOVID™

11.16.2022

Pfizer and BioNTech Advance Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T cell Responses and Duration of Protection

11.03.2022

Pfizer and BioNTech Initiate Phase 1 Study of Single Dose mRNA-Based Combination Vaccine Candidate for Influenza and COVID-19